Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer.
Matulonis UA, Wulf GM, Barry WT, Birrer M, Westin SN, Farooq S, Bell-McGuinn KM, Obermayer E, Whalen C, Spagnoletti T, Luo W, Liu H, Hok RC, Aghajanian C, Solit DB, Mills GB, Taylor BS, Won H, Berger MF, Palakurthi S, Liu J, Cantley LC, Winer E.
Matulonis UA, et al. Among authors: westin sn.
Ann Oncol. 2017 Mar 1;28(3):512-518. doi: 10.1093/annonc/mdw672.
Ann Oncol. 2017.
PMID: 27993796
Free PMC article.
Clinical Trial.